Deal overview

Resonetics announced on 23 March 2026 that it has completed the acquisition of Resolution Medical, a transaction the company says will broaden its end-to-end development and manufacturing capabilities for interventional, structural heart, and neuromodulation devices. The acquisition integrates Resolution Medical's biosimulation, product design, NPI and cleanroom assembly expertise with Resonetics' precision component manufacturing, AGILE Product Development® capabilities, and battery and electronic technologies.

Strategic capabilities added

The combined organization brings together complementary technical strengths important to advanced neurotechnology: precision microfabrication and laser processing; nitinol and thin-wall metal tubing; photochemical machining; plus electronics, lead and implantable/external pulse generator (IPG/EPG) design and battery development. Resonetics highlights that the deal expands finished-device and sub-assembly capabilities and supports the full device lifecycle from early concept through scaled commercialization.
Enhanced design-to-production integration, enabling earlier consideration of manufacturing constraints in engineering and reducing design iteration cycles.
Expanded cleanroom assembly and NPI resources for regulated device programs, including implantables and combination electronics.
Greater in-house component content (leads, batteries, IPGs/EPGs) to shorten supply chains and simplify vendor coordination.

Leadership perspectives

"This marks an important milestone in Resonetics' growth strategy," said Kevin Kelly, CEO of Resonetics. He emphasized that device complexity across regulated medical markets increasingly requires partners who can manage integrated programs at scale. Peter Herman, CEO of Resolution Medical, said the team will leverage Resonetics' global manufacturing depth and technical resources while maintaining the responsiveness customers expect.

Implications for neuromodulation and neurotechnology OEMs

For companies developing neuromodulation systems — including implantable stimulators, external pulse generators, and lead assemblies — the acquisition promises a more unified supply chain and earlier alignment between electrical design, battery technology, and mechanical components. Close coordination across electronics, battery systems, and microfabricated components is critical to reduce development risk and accelerate regulatory submissions for implantable neuromodulation therapies.
Potential benefits for OEMs include faster design-for-manufacturing transitions, reduced supplier management overhead, and consolidated quality systems across component and finished-device production. Resonetics' ISO 13485:2016 certification and global facility footprint (18 facilities, >3,000 associates) are positioned as enablers for scaling regulated programs internationally.

Market context and strategic rationale

Resonetics has invested in battery, lead, and IPG/EPG manufacturing in recent years to serve growing markets for implantable and external neuromodulation devices. The Resolution Medical acquisition complements those investments by adding biosimulation and early-stage engineering capabilities, which can shorten development timelines and improve program predictability. For development teams navigating increasingly complex electrical-mechanical-chemical tradeoffs in implantable neurodevices, a single partner capable of handling components through finished devices can materially reduce program risk.

Operational and regulatory notes

Resonetics is backed by private equity firms Carlyle and GTCR, and the company says the transaction builds on its strategic growth plan. The combined entity will operate under Resonetics' quality systems and aims to support customers through development, NPI, and scaled production while adhering to regulatory requirements for medical device manufacturing.

About the companies

Resonetics, founded in 1987, is an engineering and manufacturing services provider for medical devices, known for laser processing, nitinol manufacturing, thin-wall tubing, and photochemical machining, operating multiple LightSpeed Labs® and AGILE Product Development® centers globally. Resolution Medical specializes in biosimulation, device design, and cleanroom assembly for complex electromechanical medical products.

Takeaway

The acquisition positions Resonetics as a more integrated manufacturing and development partner for neuromodulation and interventional device OEMs. By combining design, biosimulation, precision components, and battery/electronics capabilities under one platform, Resonetics aims to reduce program complexity and accelerate commercialization timelines for regulated neurotechnology products.

Photo credit: mma.prnewswire.com

Tags: acquisition, neuromodulation, medical devices, manufacturing

Topics: Neurotech industry & startups, Neuromodulation, Neuroprosthetics & neural implants